Keratosis pilaris‐like eruption secondary to nilotinib in a child
Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous...
Gespeichert in:
| Veröffentlicht in: | Pediatric dermatology 2020-09, Vol.37 (5), p.968-969 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 969 |
|---|---|
| container_issue | 5 |
| container_start_page | 968 |
| container_title | Pediatric dermatology |
| container_volume | 37 |
| creator | Oro‐Ayude, Marcos Feito, Marta Quintana‐Castanedo, Lucía Beato‐Merino, Maria Jose De Lucas, Raúl |
| description | Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy. |
| doi_str_mv | 10.1111/pde.14267 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2446347401</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2446347401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-2b31479ef1d4a62f1d8a0a31d930deddc58fe530893bc94d8ec4f3f533b12fcf3</originalsourceid><addsrcrecordid>eNp1kLtOwzAYhS0EoqUw8ALIEhNDWt_ipCMq5SKQYIDZcnwRLmkc7ESoG4_AM_IkGFLY-JezfPr-owPAMUZTnG7WajPFjPBiB4xxTvIMswLtgjEqKM9KxPgIHMS4QgiVnON9MKKEI4ILPgaLWxNk56OLsHW1DC5-vn_U7sVAE_q2c76B0SjfaBk2sPOwcbXvXOMq6BoooXp2tT4Ee1bW0RxtcwKeLpePi-vs7v7qZnF-lyma0yIjFU295sZizSQnKUqJJMV6TpE2Wqu8tCanqJzTSs2ZLo1iltqc0goTqyydgNPB2wb_2pvYiZXvQ5NeCsIYp6xgCCfqbKBU8DEGY0Ub3DrVFxiJ77lEmkv8zJXYk62xr9ZG_5G_-yRgNgBvrjab_03i4WI5KL8AiNx0xQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446347401</pqid></control><display><type>article</type><title>Keratosis pilaris‐like eruption secondary to nilotinib in a child</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Oro‐Ayude, Marcos ; Feito, Marta ; Quintana‐Castanedo, Lucía ; Beato‐Merino, Maria Jose ; De Lucas, Raúl</creator><creatorcontrib>Oro‐Ayude, Marcos ; Feito, Marta ; Quintana‐Castanedo, Lucía ; Beato‐Merino, Maria Jose ; De Lucas, Raúl</creatorcontrib><description>Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.14267</identifier><identifier>PMID: 32602176</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Abnormalities, Multiple ; Adolescent ; Antineoplastic Agents ; BCR‐ABL‐positive ; Case reports ; chronic ; Chronic myeloid leukemia ; Darier Disease ; Enzyme inhibitors ; Eyebrows - abnormalities ; Fusion Proteins, bcr-abl ; Humans ; Imatinib ; Inhibitor drugs ; Intolerance ; Keratosis ; Leukemia ; myelogenous ; Myeloid leukemia ; Pediatrics ; protein kinase inhibitors ; Protein Kinase Inhibitors - adverse effects ; Protein-tyrosine kinase ; Pyrimidines - adverse effects ; Side effects ; Skin diseases ; Skin eruptions ; Targeted cancer therapy</subject><ispartof>Pediatric dermatology, 2020-09, Vol.37 (5), p.968-969</ispartof><rights>2020 Wiley Periodicals LLC.</rights><rights>Copyright © 2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-2b31479ef1d4a62f1d8a0a31d930deddc58fe530893bc94d8ec4f3f533b12fcf3</citedby><cites>FETCH-LOGICAL-c3537-2b31479ef1d4a62f1d8a0a31d930deddc58fe530893bc94d8ec4f3f533b12fcf3</cites><orcidid>0000-0001-5136-841X ; 0000-0002-4222-9343 ; 0000-0002-2645-8904</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpde.14267$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpde.14267$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32602176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oro‐Ayude, Marcos</creatorcontrib><creatorcontrib>Feito, Marta</creatorcontrib><creatorcontrib>Quintana‐Castanedo, Lucía</creatorcontrib><creatorcontrib>Beato‐Merino, Maria Jose</creatorcontrib><creatorcontrib>De Lucas, Raúl</creatorcontrib><title>Keratosis pilaris‐like eruption secondary to nilotinib in a child</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.</description><subject>Abnormalities, Multiple</subject><subject>Adolescent</subject><subject>Antineoplastic Agents</subject><subject>BCR‐ABL‐positive</subject><subject>Case reports</subject><subject>chronic</subject><subject>Chronic myeloid leukemia</subject><subject>Darier Disease</subject><subject>Enzyme inhibitors</subject><subject>Eyebrows - abnormalities</subject><subject>Fusion Proteins, bcr-abl</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Inhibitor drugs</subject><subject>Intolerance</subject><subject>Keratosis</subject><subject>Leukemia</subject><subject>myelogenous</subject><subject>Myeloid leukemia</subject><subject>Pediatrics</subject><subject>protein kinase inhibitors</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein-tyrosine kinase</subject><subject>Pyrimidines - adverse effects</subject><subject>Side effects</subject><subject>Skin diseases</subject><subject>Skin eruptions</subject><subject>Targeted cancer therapy</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAYhS0EoqUw8ALIEhNDWt_ipCMq5SKQYIDZcnwRLmkc7ESoG4_AM_IkGFLY-JezfPr-owPAMUZTnG7WajPFjPBiB4xxTvIMswLtgjEqKM9KxPgIHMS4QgiVnON9MKKEI4ILPgaLWxNk56OLsHW1DC5-vn_U7sVAE_q2c76B0SjfaBk2sPOwcbXvXOMq6BoooXp2tT4Ee1bW0RxtcwKeLpePi-vs7v7qZnF-lyma0yIjFU295sZizSQnKUqJJMV6TpE2Wqu8tCanqJzTSs2ZLo1iltqc0goTqyydgNPB2wb_2pvYiZXvQ5NeCsIYp6xgCCfqbKBU8DEGY0Ub3DrVFxiJ77lEmkv8zJXYk62xr9ZG_5G_-yRgNgBvrjab_03i4WI5KL8AiNx0xQ</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Oro‐Ayude, Marcos</creator><creator>Feito, Marta</creator><creator>Quintana‐Castanedo, Lucía</creator><creator>Beato‐Merino, Maria Jose</creator><creator>De Lucas, Raúl</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0001-5136-841X</orcidid><orcidid>https://orcid.org/0000-0002-4222-9343</orcidid><orcidid>https://orcid.org/0000-0002-2645-8904</orcidid></search><sort><creationdate>202009</creationdate><title>Keratosis pilaris‐like eruption secondary to nilotinib in a child</title><author>Oro‐Ayude, Marcos ; Feito, Marta ; Quintana‐Castanedo, Lucía ; Beato‐Merino, Maria Jose ; De Lucas, Raúl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-2b31479ef1d4a62f1d8a0a31d930deddc58fe530893bc94d8ec4f3f533b12fcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abnormalities, Multiple</topic><topic>Adolescent</topic><topic>Antineoplastic Agents</topic><topic>BCR‐ABL‐positive</topic><topic>Case reports</topic><topic>chronic</topic><topic>Chronic myeloid leukemia</topic><topic>Darier Disease</topic><topic>Enzyme inhibitors</topic><topic>Eyebrows - abnormalities</topic><topic>Fusion Proteins, bcr-abl</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Inhibitor drugs</topic><topic>Intolerance</topic><topic>Keratosis</topic><topic>Leukemia</topic><topic>myelogenous</topic><topic>Myeloid leukemia</topic><topic>Pediatrics</topic><topic>protein kinase inhibitors</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein-tyrosine kinase</topic><topic>Pyrimidines - adverse effects</topic><topic>Side effects</topic><topic>Skin diseases</topic><topic>Skin eruptions</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oro‐Ayude, Marcos</creatorcontrib><creatorcontrib>Feito, Marta</creatorcontrib><creatorcontrib>Quintana‐Castanedo, Lucía</creatorcontrib><creatorcontrib>Beato‐Merino, Maria Jose</creatorcontrib><creatorcontrib>De Lucas, Raúl</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oro‐Ayude, Marcos</au><au>Feito, Marta</au><au>Quintana‐Castanedo, Lucía</au><au>Beato‐Merino, Maria Jose</au><au>De Lucas, Raúl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Keratosis pilaris‐like eruption secondary to nilotinib in a child</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>37</volume><issue>5</issue><spage>968</spage><epage>969</epage><pages>968-969</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14‐year‐old patient being treated with nilotinib who developed a keratosis pilaris‐like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32602176</pmid><doi>10.1111/pde.14267</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-5136-841X</orcidid><orcidid>https://orcid.org/0000-0002-4222-9343</orcidid><orcidid>https://orcid.org/0000-0002-2645-8904</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0736-8046 |
| ispartof | Pediatric dermatology, 2020-09, Vol.37 (5), p.968-969 |
| issn | 0736-8046 1525-1470 |
| language | eng |
| recordid | cdi_proquest_journals_2446347401 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Abnormalities, Multiple Adolescent Antineoplastic Agents BCR‐ABL‐positive Case reports chronic Chronic myeloid leukemia Darier Disease Enzyme inhibitors Eyebrows - abnormalities Fusion Proteins, bcr-abl Humans Imatinib Inhibitor drugs Intolerance Keratosis Leukemia myelogenous Myeloid leukemia Pediatrics protein kinase inhibitors Protein Kinase Inhibitors - adverse effects Protein-tyrosine kinase Pyrimidines - adverse effects Side effects Skin diseases Skin eruptions Targeted cancer therapy |
| title | Keratosis pilaris‐like eruption secondary to nilotinib in a child |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T12%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Keratosis%20pilaris%E2%80%90like%20eruption%20secondary%20to%20nilotinib%20in%20a%20child&rft.jtitle=Pediatric%20dermatology&rft.au=Oro%E2%80%90Ayude,%20Marcos&rft.date=2020-09&rft.volume=37&rft.issue=5&rft.spage=968&rft.epage=969&rft.pages=968-969&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.14267&rft_dat=%3Cproquest_cross%3E2446347401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446347401&rft_id=info:pmid/32602176&rfr_iscdi=true |